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Background:  Little is known about how continuous flow left ventricular assist devices (LVAD) affect the von Willebrand factor-dependent platelet 
activation system. This is the first study to evaluate this system both before and after LVAD implantation.
Methods and Materials: Five subjects with end stage cardiomyopathy undergoing LVAD implantation were enrolled. Whole blood was obtained 
two days pre and fifteen days post LVAD implantation and levels of Factor VIII, ristocetin cofactor activity (vWF:RCo), von Willebrand antigen (vWF:Ag), 
ADAMTS13 activity, platelets, and von Willebrand multimers were measured. Patients were followed in-hospital for evaluation of clinically significant 
bleeding.
Results:  After LVAD implantation, one patient developed major bleeding, and two had minor bleeding. Hematologic assessment post LVAD 
demonstrated an increase in vWF:RCo 45 ± 84% (mean ± standard deviation) and vWF:Ag 84 ± 108% values, resulting in a 22 ± 29% decrease in 
the vWF:RCo to vWF:Ag ratio. ADAMTS13 activity decreased by 36 ± 42%. In each subject, the direction of change for ADAMTS13 opposed that seen 
with vWF:Ag. Factor VIII levels and platelets were variably affected, and multimer analysis was qualitative, prohibiting assessment of a quantitative 
change.
Conclusions:  Our evaluation of the von Willebrand factor-dependent platelet activation system after LVAD implantation found hematologic 
changes consistent with acquired type IIA von Willebrand’s disease. This likely results from a shear stress-mediated loss of high molecular weight vWF 
multimers, as evidenced by the decreased vWF:RCo to vWF:Ag ratio. These results may in part explain the increased tendency for bleeding frequently 
seen in LVAD patients. Additionally, we are the first to report a decrease in ADAMTS13 activity post LVAD. Further study is needed to determine 
whether reductions in ADAMTS13 activity result from consumption during multimer degradation, direct effects of the LVAD, or protein down regulation 
secondary to increased circulating vWF:Ag.
